Shares of Pliant Therapeutics, Inc. (NASDAQ:PLRX - Get Free Report) fell 8.7% on Friday . The stock traded as low as $10.68 and last traded at $10.91. 176,235 shares traded hands during trading, a decline of 63% from the average session volume of 472,033 shares. The stock had previously closed at $11.95.
Analyst Ratings Changes
Several research firms recently commented on PLRX. JPMorgan Chase & Co. lowered shares of Pliant Therapeutics from an "overweight" rating to a "neutral" rating in a report on Monday. Royal Bank of Canada lowered Pliant Therapeutics from an "outperform" rating to a "sector perform" rating and dropped their target price for the stock from $45.00 to $4.00 in a research report on Monday. Needham & Company LLC reduced their price target on Pliant Therapeutics from $38.00 to $10.00 and set a "buy" rating for the company in a report on Monday. HC Wainwright lowered Pliant Therapeutics from a "buy" rating to a "neutral" rating in a research report on Monday. Finally, Citigroup downgraded shares of Pliant Therapeutics from a "buy" rating to a "neutral" rating and decreased their price target for the stock from $40.00 to $4.00 in a research report on Monday. Seven analysts have rated the stock with a hold rating, three have given a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Hold" and an average target price of $17.75.
Get Our Latest Research Report on PLRX
Pliant Therapeutics Price Performance
The company has a debt-to-equity ratio of 0.09, a quick ratio of 10.26 and a current ratio of 10.26. The company's fifty day moving average price is $12.42 and its 200 day moving average price is $12.87. The firm has a market capitalization of $162.17 million, a price-to-earnings ratio of -0.80 and a beta of 1.03.
Insider Activity at Pliant Therapeutics
In other news, General Counsel Mike Ouimette sold 10,230 shares of the business's stock in a transaction on Wednesday, January 22nd. The stock was sold at an average price of $10.99, for a total transaction of $112,427.70. Following the sale, the general counsel now directly owns 70,544 shares of the company's stock, valued at $775,278.56. The trade was a 12.66 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Hans Hull sold 15,936 shares of the stock in a transaction on Friday, January 17th. The shares were sold at an average price of $11.20, for a total value of $178,483.20. Following the completion of the sale, the insider now owns 211,558 shares of the company's stock, valued at $2,369,449.60. The trade was a 7.01 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 91,855 shares of company stock worth $1,026,628 in the last three months. 6.40% of the stock is owned by company insiders.
Institutional Inflows and Outflows
Large investors have recently added to or reduced their stakes in the stock. KLP Kapitalforvaltning AS purchased a new position in shares of Pliant Therapeutics during the 4th quarter valued at $108,000. American Century Companies Inc. grew its stake in Pliant Therapeutics by 10.9% in the fourth quarter. American Century Companies Inc. now owns 100,849 shares of the company's stock valued at $1,328,000 after purchasing an additional 9,944 shares in the last quarter. Swiss National Bank increased its position in Pliant Therapeutics by 1.6% in the 4th quarter. Swiss National Bank now owns 95,700 shares of the company's stock worth $1,260,000 after purchasing an additional 1,500 shares during the last quarter. Candriam S.C.A. raised its stake in shares of Pliant Therapeutics by 8.0% during the 4th quarter. Candriam S.C.A. now owns 900,104 shares of the company's stock worth $11,854,000 after purchasing an additional 66,888 shares in the last quarter. Finally, Atria Investments Inc lifted its holdings in shares of Pliant Therapeutics by 18.1% during the 4th quarter. Atria Investments Inc now owns 11,821 shares of the company's stock valued at $156,000 after buying an additional 1,812 shares during the last quarter. Institutional investors and hedge funds own 97.30% of the company's stock.
About Pliant Therapeutics
(
Get Free Report)
Pliant Therapeutics, Inc, a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis.
Featured Stories
Before you consider Pliant Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pliant Therapeutics wasn't on the list.
While Pliant Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
